blank
logo-
Call: +66 64 505 5599

MENU

Call: +66 64 505 5599
logo-
Call: +66 64 108 5544
Call: +66 64 505 5599
Dementia

Dementia & Alzheimer’s: What They Are, How They Differ, Where Stem Cell Fits In

For many families, the moment a loved one receives a dementia diagnosis feels like the end of a road. The condition has a reputation for being untreatable — something to be managed and endured rather than addressed. That reputation is partly deserved, but the picture is more complicated than it suggests. Understanding what dementia actually is, what drives it biologically, and where emerging treatments are focused changes what options look like — and what questions are worth asking.

What is dementia?

Dementia is not a single disease. It is an umbrella term for a group of symptoms that affect memory, thinking, behaviour, and the ability to carry out daily activities — symptoms severe enough to interfere with normal functioning.

The most important thing to understand about dementia is that it is caused by damage to brain cells. Different diseases damage the brain in different ways and in different areas — and that is why different types of dementia look different clinically.

The four most common types are:

  • Alzheimer’s disease — the most common, accounting for 60–70% of all dementia cases. Caused by the abnormal accumulation of amyloid-beta plaques and tau protein tangles that progressively damage neurons throughout the brain.
  • Vascular dementia — caused by reduced blood flow to the brain, typically following a stroke or a series of smaller vascular events. Onset is often more sudden than Alzheimer’s and tends to progress in steps rather than gradually.
  • Lewy body dementia — caused by abnormal protein deposits (Lewy bodies) that disrupt brain chemistry. Often presents alongside movement symptoms similar to Parkinson’s disease.
  • Frontotemporal dementia — affects the frontal and temporal lobes primarily, causing changes in personality, behaviour, and language before memory is significantly affected. More common in younger patients, sometimes appearing in people in their 50s.

These types can overlap. Many people have mixed dementia — Alzheimer’s pathology combined with vascular changes, for example — which complicates both diagnosis and treatment.

What is the difference between dementia and Alzheimer’s?

This is one of the most common questions families ask — and the confusion is understandable.

Alzheimer’s disease is a type of dementia. Dementia is the condition; Alzheimer’s is its most common cause. Saying someone has dementia tells you what their symptoms look like. Saying they have Alzheimer’s tells you why — the specific biological process driving those symptoms.

The distinction matters clinically because different types of dementia involve different underlying pathology, progress differently, and respond differently to treatment. A person with vascular dementia and a person with Alzheimer’s disease may present similarly at first, but the biological drivers — and therefore the interventions that might help — are not the same.

What current treatments can and cannot do

Current approved treatments for dementia — primarily cholinesterase inhibitors such as donepezil, and NMDA receptor antagonists such as memantine — work by managing neurotransmitter activity in the brain. They can provide modest symptomatic benefit: slowing some aspects of cognitive decline, improving attention and daily function in some patients, for a period.

What they cannot do is stop the underlying disease process. They do not clear amyloid plaques. They do not prevent tau tangle formation. They do not repair damaged neurons or restore lost connections. Patients who respond well to these medications still decline — just sometimes more slowly.

More recently, monoclonal antibody therapies targeting amyloid — including lecanemab — have received regulatory attention for their ability to reduce amyloid burden in the brain. The results are genuine but modest, the side effect profile includes serious risks including brain swelling, and the clinical benefit in terms of meaningful cognitive function remains a subject of ongoing debate.

The gap these limitations leave is significant. For patients with early to moderate Alzheimer’s or other dementias, there is currently no treatment that halts progression, repairs existing damage, or meaningfully restores cognitive function. This is the space into which regenerative approaches are now being seriously investigated.

How stem cell therapy could help

UC-MSC therapy approaches dementia from a different direction than existing treatments. Rather than targeting a single protein or neurotransmitter pathway, it works on the biological environment of the brain — specifically the neuroinflammation and cellular dysfunction that drives ongoing neurodegeneration.

Three mechanisms are relevant:

Neuroinflammation reduction

In Alzheimer’s disease, overactivation of the brain’s immune cells (microglia) creates a chronic inflammatory state that accelerates neuronal damage — a vicious cycle in which inflammation worsens pathology and pathology worsens inflammation. UC-MSCs release anti-inflammatory signals that modulate this immune overactivation, potentially breaking the cycle.

Neuroprotection

MSCs secrete neurotrophic factors — signalling molecules that support the survival and function of existing neurons. In a brain where neurons are under progressive stress, these factors create conditions that support cellular resilience rather than accelerating cell death.

Amyloid and tau pathology

Research into UC-MSC therapy in Alzheimer’s models has found that MSCs can contribute to the clearance of amyloid-beta deposits and reduce tau pathology — effects attributed to specific cytokines secreted by the cells, including hepatocyte growth factor (HGF) and brain-derived neurotrophic factor (BDNF)

A 2025 review published in Frontiers in Cell and Developmental Biology summarised the current understanding clearly: stem cell therapy in Alzheimer’s disease exerts multi-target effects on both amyloid and tau pathology, neuroinflammation, and neural network repair — making it a fundamentally different therapeutic approach from anything currently in clinical use.

What the evidence shows

The research into stem cell therapy for dementia and Alzheimer’s disease is still developing, and this needs to be stated clearly. Most of the most compelling evidence comes from preclinical studies in animal models — where results have been consistently encouraging — and early human studies focused primarily on safety.

What the published evidence establishes so far: UC-MSC and MSC-derived therapies are safe and well-tolerated in patients with Alzheimer’s disease. Neuroinflammation is measurably reduced. Neurotrophic factor levels improve. Cognitive outcomes in early-stage patients show some signals of benefit, though the data here is not yet robust enough for firm conclusions.

A 2024 review in Frontiers in Immunology examining MSC-derived extracellular vesicles in Alzheimer’s disease found that these cell-derived signals modulate both central and peripheral immune dysfunction in ways directly relevant to AD pathology — supporting the biological rationale for this therapeutic approach.

The research is serious, the biological mechanisms are clearly defined, and the safety profile is consistently positive. What this space does not yet have is the large-scale controlled trial data that would make stem cell therapy a standard recommendation for dementia patients. Families and patients considering this approach should understand exactly where the evidence stands — and a physician who is honest about that distinction is the right person to be having this conversation with.

Who might benefit most

The patients for whom stem cell therapy is most biologically relevant are those in the early to moderate stages of dementia — where meaningful brain tissue remains, neuroinflammation is active, and the potential for slowing further damage is real.

Late-stage dementia, where extensive neuronal loss has already occurred, presents a different and more limited picture. Biological intervention at that stage cannot replace what is already gone.

For patients with elevated inflammatory markers, early cognitive changes, or a family history of Alzheimer’s disease who are not yet symptomatic, the conversation about systemic neuroinflammation management — including UC-MSC IV therapy — is one worth having proactively, before the disease burden is advanced.

Medically reviewed by Dr. Pongwat Polpong, M.D.
Neurosurgeon, Chief Physician at EDNA Wellness

Frequently asked questions

  • Is stem cell therapy a cure for dementia?

No. Stem cell therapy is not a cure for dementia or Alzheimer’s disease, and any clinic that suggests otherwise is misrepresenting the evidence. The goal is to address neuroinflammation, support neuronal health, and potentially slow disease progression — not to reverse established damage.

  • What is the difference between Alzheimer’s and dementia?

Dementia is the general term for a decline in cognitive function severe enough to affect daily life. Alzheimer’s disease is the most common cause of dementia, accounting for roughly 60–70% of cases. All Alzheimer’s patients have dementia; not all dementia patients have Alzheimer’s.

  • At what stage is stem cell therapy most relevant?

Early to moderate stages, where neuroinflammation is active and meaningful brain tissue remains. The biological rationale for intervention is strongest before extensive neuronal loss has occurred.

  • Is UC-MSC therapy safe for older patients?

The published evidence consistently shows a positive safety profile for UC-MSC therapy in older patients, including those with neurodegenerative conditions. Pre-treatment screening is required to confirm suitability.

  • How is stem cell therapy for dementia delivered?

For systemic neurological conditions like Alzheimer’s disease, intravenous (IV) infusion is the standard delivery method — allowing cells to circulate systemically and act on neuroinflammatory pathways throughout the body and brain.

  • Do I need multiple sessions?

For neurological conditions, repeat IV sessions are generally recommended — typically spaced several months apart — to sustain the anti-inflammatory and neuroprotective effects over time. The specific protocol depends on individual clinical assessment.

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

www.ednawellness.com

References

Related Posts

error:Content is protected !!
blank